Anti-CD49d Ab treatment ameliorates age-associated inflammatory response and mitigates CD8+ T-cell cytotoxicity after traumatic brain injury DOI Creative Commons
Zhangying Chen,

Kacie P. Ford,

Mecca B.A.R. Islam

и другие.

Journal of Neuroinflammation, Год журнала: 2024, Номер 21(1)

Опубликована: Окт. 19, 2024

Abstract Patients aged 65 years and older account for an increasing proportion of patients with traumatic brain injury (TBI). Older TBI experience increased morbidity mortality compared to their younger counterparts. Our prior data demonstrated that by blocking α4 integrin, anti-CD49d antibody (aCD49d Ab) abrogates CD8 + T-cell infiltration into the injured brain, improves survival, attenuates neurocognitive deficits. Here, we aimed uncover how aCD49d Ab treatment alters local cellular responses in mouse brain. Consequently, mice incur age-associated toxic cytokine chemokine long-term post-TBI. this response along a T helper (Th)1/Th17 immunological shift remediation overall cell cytotoxicity. Furthermore, reduces cells exhibiting higher effector status, leading reduced clonal expansion aged, but not young, brains chronic TBI. Together, is promising therapeutic strategy treating people.

Язык: Английский

Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance DOI Open Access

Shauna McClelland,

Pamela Maxwell,

Cristina Branco

и другие.

Cancers, Год журнала: 2024, Номер 16(16), С. 2797 - 2797

Опубликована: Авг. 8, 2024

This review delves into the intricate roles of interleukin-8 (IL-8) and its receptors, CXCR1 CXCR2, in prostate cancer (PCa), particularly castration-resistant (CRPC) metastatic CRPC (mCRPC). emphasizes crucial role tumour microenvironment (TME) inflammatory cytokines promoting progression response to cell targeting agents. IL-8, acting through C-X-C chemokine receptor type 1 (CXCR1) 2 (CXCR2), modulates multiple signalling pathways, enhancing angiogenesis, proliferation, migration cells. highlights shift PCa research focus from solely cells non-cancer-cell components, including vascular endothelial cells, extracellular matrix, immune dynamic interactions within TME. The immunosuppressive nature TME significantly influences resistance emerging therapies. Current treatment modalities, androgen deprivation therapy chemotherapeutics, encounter persistent are complicated by cancer’s notably “immune-cold” nature, which limits system tumour. These challenges underscore critical need for novel approaches that both overcome enhance engagement therapeutic potential inhibiting IL-8 is explored, with studies showing enhanced sensitivity treatments, radiation inhibitors. Clinical trials, such as ACE trial, demonstrate efficacy combining CXCR2 inhibitors existing offering significant benefits, especially patients resistant PCa. also addresses chemokines, noting complexity precision avoid side effects optimize outcomes.

Язык: Английский

Процитировано

4
Anti-CD49d Ab treatment ameliorates age-associated inflammatory response and mitigates CD8+ T-cell cytotoxicity after traumatic brain injury DOI Creative Commons
Zhangying Chen,

Kacie P. Ford,

Mecca B.A.R. Islam

и другие.

Journal of Neuroinflammation, Год журнала: 2024, Номер 21(1)

Опубликована: Окт. 19, 2024

Abstract Patients aged 65 years and older account for an increasing proportion of patients with traumatic brain injury (TBI). Older TBI experience increased morbidity mortality compared to their younger counterparts. Our prior data demonstrated that by blocking α4 integrin, anti-CD49d antibody (aCD49d Ab) abrogates CD8 + T-cell infiltration into the injured brain, improves survival, attenuates neurocognitive deficits. Here, we aimed uncover how aCD49d Ab treatment alters local cellular responses in mouse brain. Consequently, mice incur age-associated toxic cytokine chemokine long-term post-TBI. this response along a T helper (Th)1/Th17 immunological shift remediation overall cell cytotoxicity. Furthermore, reduces cells exhibiting higher effector status, leading reduced clonal expansion aged, but not young, brains chronic TBI. Together, is promising therapeutic strategy treating people.

Язык: Английский

Процитировано

0